Parallelly, eccDNA has the capability of amplifying c-myc, and the amplified copies of c-myc on eccDNA could be eliminated after administration of the anti-cancer drug hydroxyurea, thereby decreasing tumorigenicity both in vitro and in vivo.40 The gene discussed is MYC; the disease is cancer.